GlassScriptPhysician profile
Paul A Proske
NPI 1255308532
$4,155.06
in general payments reported to CMS, 2019-2025
19 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $188 · 2021: $335 · 2022: $502 · 2023: $737 · 2024: $1,382 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Entertainment: $92.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.57 |
| Entertainment | $92.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $751.86 | 2020-2025 | Total30, Argos, Precision7 |
| Johnson & Johnson Vision Care, INC. | $548.31 | 2019-2024 | Acuvue |
| Glaukos Corporation | $364.64 | 2019-2025 | Photrexa Viscous and Photrexa |
| Sun Pharmaceutical Industries INC. | $311.10 | 2020-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $294.02 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $244.09 | 2023-2024 | Miebo, Xiidra, Revive |
| Coopervision INC. | $239.30 | 2019-2024 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $236.16 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $233.60 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $125.00 | 2024 | Dextenza |
| Abbvie INC. | $114.11 | 2022 | |
| Biotissue Holdings INC. | $103.83 | 2024 | |
| Optovue, INC. | $101.40 | 2019 | |
| Shire North American Group INC | $100.18 | 2019 | |
| Sight Sciences, INC. | $100.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $94.25 | 2024 | Xdemvy |
| Optos, INC. | $92.14 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Surgical Vision, INC. | $76.65 | 2022 | |
| Allergan, INC. | $24.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Proske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.